Prestige Consumer Healthcare Inc. (NYSE:PBH) EVP Sells $743,166.00 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Prestige Consumer Healthcare Price Performance

NYSE PBH traded up $0.49 during mid-day trading on Thursday, hitting $82.81. The stock had a trading volume of 337,716 shares, compared to its average volume of 250,663. The firm’s 50 day moving average is $72.98 and its 200 day moving average is $70.09. Prestige Consumer Healthcare Inc. has a twelve month low of $56.61 and a twelve month high of $83.83. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a market capitalization of $4.09 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 2.30 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the business earned $1.07 EPS. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PBH. DA Davidson restated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $94.20.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in PBH. Boston Trust Walden Corp purchased a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth $41,785,000. Ariel Investments LLC raised its position in Prestige Consumer Healthcare by 10.7% in the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after purchasing an additional 274,212 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Prestige Consumer Healthcare by 26.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock valued at $90,891,000 after purchasing an additional 272,773 shares in the last quarter. Victory Capital Management Inc. raised its position in Prestige Consumer Healthcare by 9.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after purchasing an additional 171,357 shares in the last quarter. Finally, F M Investments LLC acquired a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at about $11,162,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.